(Q43155195)

14 November 2017

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study (English)

1 reference

14 November 2017

0 references

1 reference

12

1 reference

14 November 2017

Björn Meijers

8

0 references

Raymond Vanholder

7

object named as

Raymond Vanholder

1 reference

14 November 2017

Vincent Matthias Brandenburg

1

1 reference

14 November 2017

Georg Schlieper

2

1 reference

14 November 2017

Nicole Heussen

3

1 reference

14 November 2017

Stefan Holzmann

4

1 reference

14 November 2017

Birgit Busch

5

1 reference

14 November 2017

Pieter Evenepoel

6

1 reference

14 November 2017

Natalie Meert

9

1 reference

14 November 2017

Walter J Fassbender

10

1 reference

14 November 2017

Jürgen Floege

11

1 reference

14 November 2017

Markus Ketteler

13

1 reference

14 November 2017

language of work or name

English

0 references

publication date

18 February 2010

1 reference

Nephrology Dialysis Transplantation

14 November 2017

1 reference

14 November 2017

25

1 reference

14 November 2017

2672-2679

1 reference

14 November 2017

8

1 reference

Clinical subtypes of Alzheimer's disease.

14 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Hyperphosphatemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Nonphosphate-binding effects of sevelamer--are they of clinical relevance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Albumin-corrected calcium and ionized calcium in stable haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

The phosphatonin pathway: new insights in phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

A bench to bedside view of uremic toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Kidney failure and the gut: p-cresol and the dangers from within

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ053

21 January 2018

Identifiers

DOI

10.1093/NDT/GFQ053

1 reference

14 November 2017

1 reference